Ilya Tsimafeyeu, Director at the Bureau of Cancer Research, shared a post on Facebook:
“In this article, I explored a provocative question: could locking FGFR1 be the key to enhancing the power of immunotherapy?”
Title: Future perspectives: targeting fibroblast growth factor receptor 1 to enhance the efficacy of immunotherapy
Author: Ilya Tsimafeyeu
Read The Full Article at Open Exploration.
More posts featuring Ilya Tsimafeyeu on OncoDaily.